

**7-5/2013/EU/WC-0144**  
**Government of India**  
**Directorate General of Health Services**  
**Central Drugs Standard Control Organisation**  
**(International Cell)**

FDA Bhawan, Kotla Road,  
New Delhi-110002

Dated:

**28 JAN 2020**

To  
**M/s. Cipla Limited,**  
**D-7, MIDC, Industrial Area, Kurkumbh,**  
**Taluka: Daund, District: Pune -Zone4- 413 802**  
**Maharashtra, India**

**Subject:- Written Confirmation of M/s. Cipla Limited, D-7, MIDC, Industrial Area, Kurkumbh, Taluka: Daund, District: Pune- Zone4- 413 802, Maharashtra, India as per requirement of EU for import of active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India-Reg.**

Sir,

Please refer to your application submitted to CDSCO, West Zone office Mumbai and the recommendation received from DDC(I), West Zone Mumbai on the above noted subject.

Written Confirmation as required for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India is herewith granted subject to the following conditions:-

1. The Active Pharmaceutical Ingredients shall confirm to Good Manufacturing Practices mentioned in the EU directives or other equivalent (GMP of WHO/ICH Q7).
2. The manufacturer is subject to regular, strict and transparent controls and to the effective enforcement of Good Manufacturing Practice, including repeated and unannounced inspections, so as to ensure a protection of public health equivalent to that in the EU.
3. The manufacturer is required to follow the Guidance document for Issue of Written Confirmation as issued by CDSCO.
4. Written Confirmation shall be produced by the Authorized Exporter as and when required by the Drug Regulatory Authority.
5. The Written Confirmation will be withdrawn in the events of non compliance of Standards.
6. This Written Confirmation, unless it is sooner suspended or cancelled, shall be valid for a period of three years.

7. In the event of any Non Compliance observed during inspections conducted by Local or International Drug Authorities, the same shall be forwarded to this office within 7 days of receipt of report.
8. In the event of any drug found not of standard quality, the same shall be reported to this office within 7 days of receipt of report.

Please note that Written Confirmation issued is liable to be suspended / cancelled, if any of the conditions stipulated above are not complied with or in case of violation of the provisions of the Drugs & Cosmetics Act, 1940 and the Rules thereunder as the case may be.

Please acknowledge the receipt.

Annexure No.	No. of Products	Date of Issue	Valid Upto
1	24	09.09.2019	08.09.2022
2	04	09.09.2019	08.09.2022
3	04	01.10.2019	08.09.2022
4	02	13.12.2019	08.09.2022
5	05	28 JAN 2020	08.09.2022

Yours faithfully,

(Dr. V.G. Somani)  
Drugs Controller General (India)

o/c

23.01.2020  
12



GOVERNMENT OF INDIA  
MINISTRY OF HEALTH & FAMILY WELFARE  
Central Drugs Standard Control Organization

CERTIFICATE NO. :

Annexure-05  
WC-0144

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

Name and address of site: M/s. Cipla Limited,  
D-7, MIDC, Industrial Area, Kurkumbh,  
Taluka: Daund, District: Pune- Zone4- 413 802  
Maharashtra, India

List of APIs:

S. No.	Active substance(s)	Activity(ies)
1.	Arformoterol Tartrate	Manufacturing & Packing
2.	Albendazole USP	Manufacturing & Packing
3.	Cinacalcet Hydrochloride	Manufacturing & Packing
4.	Mebendazole USP	Manufacturing & Packing
5.	Rizatriptan Benzoate BP/Ph.Eur/USP	Manufacturing & Packing

ITEM(S) Five (05) Only

The Written Confirmation remains valid until: 08<sup>th</sup> September, 2022

Signature

Stamp of the authority and date



28 JAN 2020

o/c  
23-01-2020  
R